Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
Bluejay Diagnostics, Inc. (BJDX)
Company Research
Source: GlobeNewswire
ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the Company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness. SYMON-II Clinical trialsBluejay is successfully enrolling across all participating sites in its SYMON™ II multicenter IL-6 monitoring study, with a total of 545 patients enrolled with a target of 750 patients, exceeding initial expectations. All enrollments are under approved IRB protocols. Management believes the scale and diversity of the dataset will meaningfully strengthen the Company’s regulatory positioning and support future partner and stakeholder discussions. Current progress materially reduces enrollmen
Show less
Read more
Impact Snapshot
Event Time:
BJDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BJDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BJDX alerts
High impacting Bluejay Diagnostics, Inc. news events
Weekly update
A roundup of the hottest topics
BJDX
News
- Bluejay Diagnostics Announces All Prefunded Warrants Now ExercisedGlobeNewswire
- Bluejay Diagnostics announces 1-for-4 reverse stock split [Seeking Alpha]Seeking Alpha
- Bluejay Diagnostics Announces 1-for-4 Reverse Stock SplitGlobeNewswire
- Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production [Yahoo! Finance]Yahoo! Finance
- Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody ProductionGlobeNewswire
BJDX
Sec Filings
- 2/20/26 - Form 8-K
- 2/18/26 - Form SCHEDULE
- 2/18/26 - Form 8-K
- BJDX's page on the SEC website